Foamix, a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne, impetigo and other skin conditions. Foamix’s leading products target moderate-to-severe acne and impetigo. In March 2020, Foamix completed a merger with VYNE Therapeutics Inc., a biotech company publicly traded on NASDAQ (VYNE).